LncRNA C9orf139 can regulate the growth of pancreatic cancer by mediating the miR-663a/Sox12 axis

Table 1 Relationship between long non-coding RNA C9orf139 and pathological data of patients

Variable		LncRNA C9orf139		χ2	P value
		High expression (n = 27)	Low expression (n = 27)
Age				0.260	1.271
	≥ 60 yr (n = 20)	12 (44.44)	8 (29.63)
	< 60 yr (n = 34)	15 (55.56)	19 (70.37)
Sex				0.307	0.580
	Male (n = 32)	15 (55.56)	17 (62.96)
	Female (n = 22)	12 (44.44)	10 (37.04)
Tumor size				0.333	0.564
	≥ 3 cm (n = 18)	10 (37.04)	8 (29.63)
	< 3 cm (n = 36)	17 (62.96)	19 (70.37)
TNM stage				9.826	0.002
	I-II (n = 35)	12 (44.44)	23 (85.19)
	III-IV (n = 19)	15 (55.56)	4 (14.81)
Degree of differentiation				4.207	0.040
	Poor (n = 17)	12 (44.44)	5 (18.52)
	Moderate and high (n = 37)	15 (55.56)	22 (81.48)
Lymph node metastasis				5.206	0.004
	Yes (n = 13)	11 (40.74)	2 (7.41)
	No (n = 41)	16 (59.26)	25 (92.59)

LncRNA: Long non-coding RNA; TNM: Tumor-node-metastasis.

Table 2 Prognostic analysis of long non-coding RNA C9orf139 in patients

Variable	Univariate Cox regression analysis			Multivariate Cox regression analysis
	P value	HR	95CI%	P value	HR	95CI%
Age (≥ 60 yr vs < 60 yr)	0.637	1.158	0.631-2.125
Sex (male vs female)	0.885	0.957	0.528-1.734
Tumor size (≥ 3 cm vs < 3 cm)	0.160	0.648	0.354-1.187
TNM stage (I + II vs III + IV)	0.035	1.932	1.047-3.564	0.109	1.724	0.886-3.353
Degree of differentiation (poor vs moderate and high)	0.019	0.477	0.257-0.886	0.045	0.526	0.281-0.987
Lymph node metastasis (yes vs no)	0.019	0.456	0.237-0.877	0.167	0.622	0.317-1.219
C9orf139 (low expression vs high expression)	0.010	0.455	0.251-0.825	0.020	0.488	0.267-0.893

TNM: Tumor-node-metastasis.